Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Blinatumomab plus ponatinib for ALL update coming soon at EHA 2021

Nicholas Short • 25 May 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Antibodies Blinatumomab Ponatinib

Nicholas Short, MD, MD Anderson Cancer Center, Houston, TX, discussess an update on blinatumomab plus ponatinib which will be presented at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Nicholas Short, MD, has received consulting fees from Takeda Oncology and AstraZeneca; has received research funding from Takeda Oncology and Astellas Pharma Inc., and has received honoraria from Amgen.

More from Nicholas Short

2:50
The impact of induction therapy on post-transplant outcomes in AML
Nicholas Short • 6 Sep 2023
2:20
Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMML
Nicholas Short • 6 Sep 2023
2:30
The importance of MRD-guided therapy in ALL
Nicholas Short • 6 Sep 2023
2:40
The role of PCR and NGS-based MRD in Ph+ ALL
Nicholas Short • 6 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals